Navigation Links
Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
Date:3/18/2008

MONTREAL, March 18 /PRNewswire/ - Aegera Therapeutics announced today the initiation of a Phase 1, first-in-man, clinical trial for AEG33773, a novel, orally bioavailable small molecule in development for the treatment of painful diabetic neuropathy. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of AEG33773 using a randomized, double blind, placebo controlled, single ascending dose design in healthy male volunteers.

Aegera completed a comprehensive pre-clinical development program on AEG33773, culminating in regulatory clearance from Health Canada and treatment of a first patient, in less than 12 months.

"We are extremely excited about the potential for AEG33773 to treat painful diabetic neuropathy and to expand to other pain and neuropathy indications, based on our extensive preclinical experience with this family of compounds in multiple models of pain and neuropathy," commented Dr. Jon Durkin, Vice-President Research and Preclinical Development at Aegera.

"This important milestone was achieved in record time, as the Aegera team has successfully filed regulatory applications for two potential blockbuster compounds, AEG33773 and AEG40826, in the last three months while initiating multiple Phase 2 trials for our lead program AEG35156. Aegera now has four unique programs in clinical development and is poised to deliver significant clinical data over the next 12-18 months" added Dr. Michael J. Berendt, Aegera's President and CEO.

About AEG33773

AEG33773 was developed as an orally bioavailable small molecule compound which provides acute pain relief in preclinical models of neuropathic and inflammatory pain. In addition, AEG33773's unique mechanism of action has demonstrated excellent in vivo activity in models of diabetic neuropathy with respect to its ability to not only prevent, but also to reverse established neuropathies.

About Aegera Therapeutics Inc.

Aegera Therapeutic
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fertility Associates ... Donor Egg Bank USA , a network of more ... Through this partnership, patients have fast access to a ... vitro fertilization, IVF . Fertility Associates of Memphis is ... this fertility treatment option. , Dr. William Kutteh ...
(Date:12/19/2014)... -- Naurex Inc., a biopharmaceutical company leveraging its unique ... central nervous system, today announced that Norbert Riedel ... at the 33 rd annual J.P. Morgan Healthcare ... p.m. PST on Tuesday, January 13, 2015, at the ... About Naurex Inc. ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Pharmaceuticals,Inc. (Nasdaq: VNDA ), a biopharmaceutical company ... candidates for central,nervous system disorders, today announced financial ... 30, 2008., Vanda reported research and development ... $3.8 million, compared to $5.5 million in the ...
... Identify Predisposition to Early Cardiovascular,Events in Asian Populations, ... (Amex: ILI ), announced today that Kenneth ... new research findings on,the genetics of cardiovascular disease ... which takes place from Oct. 31 -,Nov. 1, ...
... on the DBTSS, Pfam and PDB databases enable ,researchers to quickly ... ... 2008 -- OpenHelix today announced the availability of newly updated ... the Protein Databank (PDB). DBTSS is a public resource for ...
Cached Biology Technology:Vanda Pharmaceuticals Reports Third Quarter 2008 Results 2Vanda Pharmaceuticals Reports Third Quarter 2008 Results 3Vanda Pharmaceuticals Reports Third Quarter 2008 Results 4Vanda Pharmaceuticals Reports Third Quarter 2008 Results 5Vanda Pharmaceuticals Reports Third Quarter 2008 Results 6Vanda Pharmaceuticals Reports Third Quarter 2008 Results 7Vanda Pharmaceuticals Reports Third Quarter 2008 Results 8Vanda Pharmaceuticals Reports Third Quarter 2008 Results 9Vanda Pharmaceuticals Reports Third Quarter 2008 Results 10Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium 2Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium 3Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium 4Updated Online Tutorials for DBTSS, Pfam and PDB 2Updated Online Tutorials for DBTSS, Pfam and PDB 3
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... at the Institute of Food Research, which is ... of virus-produced proteins that destroy bacterial cells to ... proteins that specifically target certain bacteria, and IFR ... difficile , a common and dangerous source of ...
... five-year grant is considered a long-term grant, Alan R. Templeton, PhD, ... in St. Louis, has managed to follow some of the species ... in his career he studied parthenogenesis, or virgin birth, in fruit ... "Drosophilia have fast generation times," he says, "but I studied ...
... ReportsnReports   announces it will carry Market Research Reports on ... Image-Guided Surgery)   in its store A. ... Cell Arrays) Trends & Global Forecast (2010-2015) ... key applications. It was valued at $2.6 billion in 2010 ...
Cached Biology News:Tuning natural antimicrobials to improve their effectiveness at battling superbugs 2Restoration as science: case of the collared lizard 2Restoration as science: case of the collared lizard 3Restoration as science: case of the collared lizard 4Restoration as science: case of the collared lizard 5Restoration as science: case of the collared lizard 6Restoration as science: case of the collared lizard 7Restoration as science: case of the collared lizard 8Restoration as science: case of the collared lizard 9ReportsnReports - Biochips Market, Nuclear Medicine Market, Medical Imaging Market Research 2ReportsnReports - Biochips Market, Nuclear Medicine Market, Medical Imaging Market Research 3ReportsnReports - Biochips Market, Nuclear Medicine Market, Medical Imaging Market Research 4ReportsnReports - Biochips Market, Nuclear Medicine Market, Medical Imaging Market Research 5
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human GFR alpha-4 Affinity Purified Polyclonal Ab...
Human Siglec-9 Biotinylated Affinity Purified Pab...
Human MFRP MAb (Clone 291218)...
Biology Products: